Hemab Therapeutics Holdings, Inc.
COAG$1.44B
Small CapNASDAQBiotechnology🇺🇸North America59 employees
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Jul 15, 2026
8wMarket Overview
Stock performance and key metrics
COAG News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Sutacimig
Congenital Factor VII Deficiency
HMB-002 (Part A)
Von Willebrand Disease (VWD)
HMB-001
Glanzmann Thrombasthenia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Sutacimig | Phase 2 | Congenital Factor VII Deficiency | - | - |
HMB-002 (Part A) | Phase 2 | Von Willebrand Disease (VWD) | - | - |
HMB-001 | Phase 2 | Glanzmann Thrombasthenia | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply